Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?
Year: 2017
Type: review
Abstract: Cardiotoxic effects from cancer therapy are a major cause of morbidity during cancer treatment. Unexpected toxicity can occur during treatment and/or after completion of therapy, into the time of cancer survivorship. While older drugs such as anthracyclines have well-known cardiotoxic effects, newer drugs such as tyrosine kinase inhibitors, proteasome inhibitors, and immunotherapies also can cause diverse cardiovascular and metabolic complications. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are increasingly being used as instruments for disease modelling, drug discovery, and mechanistic toxicity studies. Promising results with hiPSC-CM chemotherapy studies are raising hopes for improving cancer therapies through personalized medicine and safer drug development. Here, we review the cardiotoxicity profiles of common chemotherapeutic agents as well as efforts to model them in vitro using hiPSC-CMs.
Source: European Heart Journal
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1025848449, G1073836588, Modeling Endothelial Dysfunction in LMNA-related Dilated Cardiomyopathy, G2673274569, G2776647444, Modeling Susceptibility to Chemotherapy-Induced Cardiotoxicity Using Human iPSCs, G3549828030, G5316616671, G5520316217, Assessment of Low-Dose Radiation Risk and Mechanisms of Individual Radiosensitivity, Genome Editing of Human iPSCs to Study Inherited Hypertrophic Cardiomyopathy, Precision Medicine and Clinical Trial in a Dish for Cardiovascular Diseases, G7018652729, Comparative Medicine Biosciences Training Program, Human Induced Pluripotent Stem Cells for Cardiovascular Disease Modeling, G973603016
OpenAlex ID: W2789694194